274 related articles for article (PubMed ID: 26360705)
21. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.
Liu H; Tekle C; Chen YW; Kristian A; Zhao Y; Zhou M; Liu Z; Ding Y; Wang B; Mælandsmo GM; Nesland JM; Fodstad O; Tan M
Mol Cancer Ther; 2011 Jun; 10(6):960-71. PubMed ID: 21518725
[TBL] [Abstract][Full Text] [Related]
22. Acylglycerol kinase promotes paclitaxel resistance in nasopharyngeal carcinoma cells by regulating FOXM1 via the JAK2/STAT3 pathway.
Zhao C; Chen HY; Zhao F; Feng HJ; Su JP
Cytokine; 2021 Dec; 148():155595. PubMed ID: 34116927
[TBL] [Abstract][Full Text] [Related]
23. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
24. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Farhadi E; Zaker F; Safa M; Rezvani MR
Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
[TBL] [Abstract][Full Text] [Related]
25. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
[TBL] [Abstract][Full Text] [Related]
26. Involvement of nuclear JAK2 signaling in AG490-induced apoptosis of gastric cancer cells.
Qian C; Wang J; Yao J; Wang L; Xue M; Liu W; Si J
Anat Rec (Hoboken); 2013 Dec; 296(12):1865-73. PubMed ID: 24151255
[TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
[TBL] [Abstract][Full Text] [Related]
28. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
[TBL] [Abstract][Full Text] [Related]
29. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
[TBL] [Abstract][Full Text] [Related]
30. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
31. Hospicells promote upregulation of the ATP-binding cassette genes by insulin-like growth factor-I via the JAK2/STAT3 signaling pathway in an ovarian cancer cell line.
Benabbou N; Mirshahi P; Cadillon M; Soria J; Therwath A; Mirshahi M
Int J Oncol; 2013 Sep; 43(3):685-94. PubMed ID: 23857432
[TBL] [Abstract][Full Text] [Related]
32. Effect of the JAK2/STAT3 signaling pathway on nerve cell apoptosis in rats with white matter injury.
Chen XM; Yu YH; Wang L; Zhao XY; Li JR
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):321-327. PubMed ID: 30657573
[TBL] [Abstract][Full Text] [Related]
33. Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells.
Huang WL; Yeh HH; Lin CC; Lai WW; Chang JY; Chang WT; Su WC
Mol Cancer; 2010 Dec; 9():309. PubMed ID: 21122157
[TBL] [Abstract][Full Text] [Related]
34. Modulation of drug resistance in ovarian cancer cells by inhibition of protein kinase C-alpha (PKC-α) with small interference RNA (siRNA) agents.
Zhao LJ; Xu H; Qu JW; Zhao WZ; Zhao YB; Wang JH
Asian Pac J Cancer Prev; 2012; 13(8):3631-6. PubMed ID: 23098446
[TBL] [Abstract][Full Text] [Related]
35. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
[TBL] [Abstract][Full Text] [Related]
36. Janus-activated kinases and signal transducer and activator of transcription control tumor growth response to camptothecin in human colon cancer cells.
Yun HJ; Kim SY; Kwon YY; Kim CH; Kang CM; Kim EJ
Cancer Biol Ther; 2010 Aug; 10(4):354-61. PubMed ID: 20534983
[TBL] [Abstract][Full Text] [Related]
37. The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells.
Lu M; Xiao L; Li Z
J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):725-8. PubMed ID: 18231754
[TBL] [Abstract][Full Text] [Related]
38. Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.
Yang Y; Wang Z; Li M; Lu S
J Huazhong Univ Sci Technolog Med Sci; 2009 Apr; 29(2):239-42. PubMed ID: 19399413
[TBL] [Abstract][Full Text] [Related]
39. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
40. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]